ObsEva Reports First Quarter 2018 Financial Results and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
63
ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update

-Key First Quarter 2018 Clinical Milestones Achieved

  • Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109 in Endometriosis, results expected by the end of Q2:18, and  
  • Primary endpoint achieved in Phase 3 IMPLANT2 trial of nolasiban in IVF, Live Birth Rate data expected in Q4:18

Geneva, Switzerland and Boston, MA - May 16, 2018 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy, today reported financial results for the quarter ended March 31, 2018, and provided a business update outlining recent corporate progress and upcoming milestones.

"2018 is off to a very good start for ObsEva, with the first quarter announcement of positive IMPLANT2 phase 3 results for nolasiban in IVF" said Ernest Loumaye, co-founder and Chief Executive Officer of ObsEva. "Along with our GnRH antagonist OBE2109, we now believe that we have two late clinical-stage compounds with the potential to significantly improve the treatment of important medical conditions that impact the lives of millions of women globally".

Recent Pipeline Highlights

  • Positive Phase 3 IMPLANT 2 trial top line results were disclosed in February 2018 for ObsEva's oral oxytocin receptor antagonist nolasiban, given as a single dose, 4 hours prior to a single embryo transfer (ET) and designed to improve clinical pregnancy and live birth rates in women undergoing in-vitro fertilization (IVF).  The primary endpoint was achieved, with a 10-week ongoing pregnancy rate of 35.6% for nolasiban treated patients vs. 28.5% for placebo treated patients, a 25% relative increase (p= 0.031).  In the ET Day 5 subgroup, the relative increase was 32% and the absolute increase was 11.2% in favor of nolasiban (nolasiban 45.9% and placebo 34.7%, p = 0.034). In addition, nolasiban treatment was safe and well tolerated with no difference in rates of discontinuation from treatment emergent adverse events (TEAE's) nor the incidence of serious adverse events (SAE's) as compared to placebo.   
  • Patient randomization was completed in the first quarter of 2018 for the EDELWEISS Phase 2b clinical trial of OBE2109, ObsEva's oral GnRH receptor antagonist for the treatment of endometriosis.  The trial enrolled nearly 330 patients combined in Europe and the U.S., and is comparing 4 different doses of OBE2109 to placebo, with the goal of identifying dosages that can alleviate pain symptoms utilizing either partial or full estrogen suppression to offer  potential alternatives both with and without hormonal add back therapy (ABT).  
  • Patient enrollment continued in the PRIMROSE 1 and PRIMROSE 2 Phase 3 clinical trials of OBE2109 for the treatment of uterine fibroids, with a target enrollment of approximately 1,000 women in total (US and Europe). These trials  are designed to reduce heavy menstrual bleeding (HMB) associated with uterine fibroids, with efficacy and safety of  2 doses being studied, one with ABT and one without ABT.  
  • First patients were enrolled in the PROLONG Phase 2a clinical trial of OBE022, ObsEva's oral prostaglandin F2 alpha receptor antagonist for the treatment of pre-term labor in pregnant women between 24 and 34 weeks of gestation.

Upcoming Milestones ObsEva expects to achieve the following clinical and regulatory milestones during 2018:

  • 12-week results from the Phase 2b EDELWEISS clinical trial of OBE2109 for the treatment of endometriosis, by the end of Q2:18 and readout of 24-week treatment data, including bone mineral density measurement in Q4:18. End-of-phase 2 meeting with regulatory authorities to discuss the design of the phase 3 program for that indication is expected by the end of 2018.  
  • Given current trends, completion of patient enrollment in the Phase 3 PRIMROSE 2 trial of OBE2109 for the treatment of uterine fibroids continues to be targeted for the end of 2018, while PRIMROSE 1 enrollment completion is anticipated in Q1:19  
  • Results of live birth rate and 28-day neonatal safety from the Phase 3 IMPLANT2 clinical trial of nolasiban in IVF in Q4:18. Post consultation with regulatory authorities, initiation of a US Phase 3 clinical development program is planned for Q4:18.  
  • Safety, tolerability and pharmacokinetics in pregnant women, and interim efficacy from the Phase 2a PROLONG clinical trial of OBE022 in pre-term labor in Q4:18.

First Quarter 2018 Financial Results Net loss for the first quarter of 2018 was $19.8 million, or ($0.54) per basic and diluted share, vs. $15.5 million or ($0.58) per basic and diluted share for the first quarter of 2017. Research and development expenses were $16.3 million and general and administrative expenses were $3.6 million for the quarter ended March 31, 2018, vs.  $13.1 million and $2.7 million, respectively, for the quarter ended March 31, 2017. Our first quarter 2018 net loss included non-cash expenses of $2.4 million for share-based compensation, vs.  $2.3 million in the first quarter of 2017.

As of March 31, 2018, ObsEva had cash and cash equivalents of $95.4 million.  

Conference Call Information ObsEva will host a conference call and audio webcast today at 8:00 a.m. Eastern Time, 2 p.m Central European Time, to provide a business update and discuss first quarter 2018 financial results. To participate in the conference call, please dial 844-419-1772 (U.S.) or (213) 660-0921 (international) and refer to conference ID 5663506. The webcast can be accessed under the "Investors" section of ObsEva's website www.obseva.com

About ObsEva ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit www.ObsEva.com .

Cautionary Note Regarding Forward Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan," "potential," "will," and similar expressions, and are based on ObsEva's current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of ObsEva's product candidates and the timing of enrollment in and data from clinical trials. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, ObsEva's reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in the Risk Factors section of ObsEva's Annual Report on Form 20-F for the year ended December 31, 2017, and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva's website at http://www.obseva.com . Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contact: Marion Janic RooneyPartners LLC mjanic@rooneyco.com 212-223-4017

CEO Office Contact: Shauna Dillon Shauna.dillon@obseva.ch +41 22 552 1550

Investor Contact: Mario Corso Senior Director, Investor Relations mario.corso@obseva.com 857-972-9347 office 781-366-5726 mobile

Consolidated Statements of Comprehensive Loss

   (in USD '000, except per share data)     Three-month period ended March 31,  
      2018   2017  
      Unaudited  
             
Other operating income.........     5   6  
             
OPERATING EXPENSES            
Research and development expenses....      (16,342)   (13,057)  
General and administrative expenses....     (3,649)   (2,745)  
Total operating expenses........     (19,991)   (15,802)  
             
OPERATING LOSS..........     (19,986)   (15,796)  
             
Finance income.............     155   258  
Finance expense.............     -   -  
             
NET LOSS BEFORE TAX.......     (19,831)   (15,538)  
             
Income tax benefit...........     25   -  
             
NET LOSS FOR THE PERIOD......     (19,806)   (15,538)  
             
  Net loss per share            
Basic................     (0.54)   (0.58)  
Diluted................     (0.54)   (0.58)  
Weighted Average Shares outstanding     36,389,578   26,623,553  

Consolidated Balance Sheets

(in USD '000)       March 31, 2018 December 31, 2017  
      unaudited audited  
ASSETS          
Current assets          
Cash and cash equivalents..............     95,435 110,841  
Other receivables.................     791 783  
Prepaid expenses and deferred costs..........     1,786 1,490  
Total current assets..............     98,012 113,114  
           
Non-current assets          
Furniture, fixtures and equipment.........     310 323  
Intangible assets.................     21,608 21,608  
Other long-term assets.............     192 190  
Total non-current assets.............     22,110 22,121  
           
Total assets.................     120,122 135,235  
           
LIABILITIES AND SHAREHOLDERS' EQUITY    
Current liabilities          
Current tax liability..............     27 51  
Other payables and current liabilities........     1,613 2,865  
Accrued expenses.................     10,106 6,514  
Total current liabilities..............     11,746 9,430  
           
Non-current liabilities          
Post-employment obligations..........     3,063 3.099  
Other long-term liabilities............     53 55  
Total non-current liabilities..........     3,116 3,154  
           
Shareholders' equity          
Share capital...................     2,871 2,864  
Share premium...................     220,141 219,335  
Reserves....................     8,721 7,119  
Accumulated losses...............     (126,473) (106,667)  
Total shareholders' equity...........     105,260 122,651  
           
Total liabilities and shareholders' equity....     120,122 135,235  

###

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 661

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 265

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 666

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 318

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 570

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 58

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 43

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 83

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 158

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting New Fundraising Initiative by Robin Hood for NYC

Updated Category News Views 459

Robin Hood Introduces a New Fundraising Venture In an exciting move that demonstrates their ongoing commitment to combating poverty, Robin Hood, New York's most extensive poverty-fighting organization, has launched a unique fundraising initiative titled 'The Robin Hood Pick-A-Ticker: A Fundraiser for Robin Hood (and your Favorite Charity!).' This initiative is made...

Continue Reading
Newell Brands Faces Analyst Downgrades After Earnings Release

Updated Category News Views 179

Newell Brands' Earnings Report: An Overview Newell Brands Inc. (NASDAQ: NWL) has recently reported its second-quarter earnings, revealing a mixed performance that has caught the attention of investors and analysts alike. Highlighting both earnings that met expectations and revenues that fell short, the company’s report has prompted analysts to adjust their projections...

Continue Reading
Smart Lock Market Projected Growth to US$ 16.47 Billion

Updated Category News Views 210

Smart Lock Market Value and Forecast The global smart lock market is experiencing significant growth, currently valued at approximately US$ 6.76 billion in 2024. Projections indicate that it will reach US$ 16.47 billion by 2033, showcasing a robust annual growth rate (CAGR) of 10.4% during this period. This growth can be attributed to a surge in consumer awareness...

Continue Reading
Analyzing UnitedHealth Group's Current Market Movement and Outlook

Updated Category News Views 191

Understanding the Options Activity of UnitedHealth Group In recent trading sessions, there has been notable bearish activity surrounding UnitedHealth Group (NYSE: UNH). High-profile investors seem to be indicating cautious sentiment toward this health insurance giant, which warrants the attention of retail traders. Insights from Recent Options Trading The trading data...

Continue Reading
Stan Bernard Steps Up as Zurich's New Head of Industry Practices

Updated Category News Views 261

Stan Bernard is Promoted to Lead Industry Practices at Zurich In an exciting development for Zurich North America, Stan Bernard has been appointed as the new Head of Industry Practices for the U.S. Middle Market. This significant promotion comes as Bernard takes over from Lynn Zeitler, who is retiring after an impressive 31-year career with the company. Bernard’s ascent...

Continue Reading